Literature DB >> 26590188

Ten-year follow-up of a giant prolactinoma.

Vera Fernandes1, Maria Joana Santos1, Rui Almeida2, Olinda Marques3.   

Abstract

Giant prolactinomas are rare pituitary tumours of which management can be a challenge. A 28-year-old man presented with headaches, visual impairment and behavioural changes. Clinically, the patient was found to have hypogonadism and bitemporal hemianopsia. A MRI demonstrated a pituitary tumour 76 mm in diameter and blood tests revealed a serum prolactin of 158,700 µU/mL (reference range 58-254). Initially, a craniotomy was performed. Immunohistochemistry of the tumour identified a prolactinoma with a high proliferative index and the patient was started on treatment with a dopamine agonist. A year later, neurological symptoms worsened due to regrowth of the lesion's cystic component, and so further surgery was performed. After 10 years of treatment with dopamine agonists, the prolactin levels decreased by 96.8%, there was an effective reduction in tumour size, and the neurological signs and symptoms resolved. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26590188      PMCID: PMC4680285          DOI: 10.1136/bcr-2015-212221

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.

Authors:  Victoria Delgado; Nienke R Biermasz; Sjoerd W van Thiel; See H Ewe; Nina Ajmone Marsan; Eduard R Holman; Richard A Feelders; Johannes W A Smit; Jeroen J Bax; Alberto M Pereira
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

2.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

Review 3.  Cabergoline use for pituitary tumors and valvular disorders.

Authors:  Renata S Auriemma; Rosario Pivonello; Lucia Ferreri; Prisco Priscitelli; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2014-11-04       Impact factor: 4.741

4.  Giant invasive prolactinomas.

Authors:  F Y Murphy; D L Vesely; R M Jordan; S Flanigan; P O Kohler
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

Review 5.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.

Authors:  Etienne Delgrange; Tania Daems; Johan Verhelst; Roger Abs; Dominique Maiter
Journal:  Eur J Endocrinol       Date:  2009-02-17       Impact factor: 6.664

7.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

Review 8.  Temozolomide in the management of dopamine agonist-resistant prolactinomas.

Authors:  B C Whitelaw; D Dworakowska; N W Thomas; S Barazi; P Riordan-Eva; A P King; T Hampton; D B Landau; D Lipscomb; C R Buchanan; J A Gilbert; S J B Aylwin
Journal:  Clin Endocrinol (Oxf)       Date:  2012-06       Impact factor: 3.478

9.  Giant prolactinoma: case report and review of literature.

Authors:  Masoud Rahmanian; Hamidreza Aghaei Meybodi; Bagher Larijani; Mohammad-Reza Mohajeri-Tehrani
Journal:  J Diabetes Metab Disord       Date:  2013-01-08

10.  Cabergoline treatment in invasive giant prolactinoma.

Authors:  Sadeem Alsubaie; Mussa H Almalki
Journal:  Clin Med Insights Case Rep       Date:  2014-06-19
View more
  3 in total

1.  Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.

Authors:  Ze Rui Wu; Yong Zhang; Lin Cai; Shao Jian Lin; Zhi Peng Su; Yong Xu Wei; Han Bing Shang; Wen Lei Yang; Wei Guo Zhao; Zhe Bao Wu
Journal:  Int J Endocrinol       Date:  2016-11-23       Impact factor: 3.257

2.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

3.  Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.

Authors:  Mussa H Almalki; Naji Aljohani; Saad Alzahrani; Ohoud Almohareb; Maswood M Ahmad; Abdullah A Alrashed; Fahad Alshahrani; Badurudeen Mahmood Buhary
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-06-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.